| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 07/25/2002 | US20020099222 Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them |
| 07/25/2002 | US20020099216 Compounds useful in therapy |
| 07/25/2002 | US20020099214 For prophylaxis and therapy of pruritus |
| 07/25/2002 | US20020099178 Growth-associated protease inhibitor heavy chain precursor |
| 07/25/2002 | US20020099095 For treatment and prophylactic treatment of ageing of the skin, for pretreatment or after-treatment of hair or scalp or of the hair root region, in particular before or after hair treatment, for example during colouring |
| 07/25/2002 | US20020099068 I kappa B kinase inhibitors for treating various disorders including arthritis |
| 07/25/2002 | US20020099065 Novel 3, 5, and/or 6 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents |
| 07/25/2002 | US20020099055 Novel compounds |
| 07/25/2002 | US20020099054 2-phenyl benzimidazole derivatives as MCP-1 antagonists |
| 07/25/2002 | US20020099020 Oil blend of omega-3- and omega-6- fatty acids; branched amino acid; antioxidant comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof; in a liquid nutritional matrix. |
| 07/25/2002 | US20020099009 Also diagnosing or detecting apoptosis as well as antibodies directed against the protein. |
| 07/25/2002 | US20020099008 Cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal side effects; peptide that is derived from a loop or "lollipop" region of transforming growth factor |
| 07/25/2002 | US20020098980 Sodium metasilicate, borax, sodium thiosulfate, potassium carbonate, refined sugar, water; improvement in disease resistance, weight gain rate, crop yield, crop quality, harvest time; antibody production and immune enhancement |
| 07/25/2002 | US20020098583 Composition for use in the treatment of cell cycle defects, autoimmune diseases, aging, cancer, leukemia and psoriasis |
| 07/25/2002 | US20020098573 Generating preferential vector nucleotide sequences; obtain nucleotide sequences, incubate with preferential exogenous nucleotide sequences, ligate, recover nucleotide sequences |
| 07/25/2002 | US20020098550 Nucleotide sequences coding membrane protein for use in treatment and prevention of endotoxin shock, viral disease, immflammation and tumors |
| 07/25/2002 | US20020098527 Gene recombinant antibody and antibody fragment thereof |
| 07/25/2002 | US20020098469 Extracorporeal methods for enhancing antigen presentation and immune responsiveness |
| 07/25/2002 | US20020098277 Proteins are reduced with thiol redox proteins and further reacted with cystamine or oxidized glutathione to prevent reoxidation |
| 07/25/2002 | US20020098205 Mostly comprising sodium metasilicate (pentahydrate) and shows nonspecific immunostimulating activity in plants and animals |
| 07/25/2002 | US20020098203 Immnunologically active substance embedded in microparticles consisting of starch with amylopectin content greater than 85%; non-crosslinked |
| 07/25/2002 | US20020098201 Novel myxoma genes for immune modulation |
| 07/25/2002 | US20020098199 Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
| 07/25/2002 | US20020098166 Genetically modified cells and their use in the prophylaxis or therapy of disorders |
| 07/25/2002 | CA2435260A1 Receptors and membrane-associated proteins |
| 07/25/2002 | CA2435121A1 Histamine receptor antagonists |
| 07/25/2002 | CA2435077A1 Preparation for improved dietary utilisation |
| 07/25/2002 | CA2434939A1 Urea derivatives as integrin alpha 4 antagonists |
| 07/25/2002 | CA2434866A1 Screening assay for cotranslational translocation interfering compounds |
| 07/25/2002 | CA2434636A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use |
| 07/25/2002 | CA2434362A1 Pluripotent adult stem cells derived from regenerative tissue |
| 07/25/2002 | CA2434350A1 Novel receptors for $i(helicobacter pylori) and use thereof |
| 07/25/2002 | CA2433879A1 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 07/25/2002 | CA2433862A1 Molecular antigen array presenting amyloid beta |
| 07/25/2002 | CA2433316A1 Molecular antigen array |
| 07/25/2002 | CA2433313A1 Polypetides and nucleic acids encoding same |
| 07/25/2002 | CA2430634A1 Proteins, polynucleotides encoding them and methods of using the same |
| 07/25/2002 | CA2430577A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 07/25/2002 | CA2427643A1 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc) |
| 07/25/2002 | CA2426775A1 Thienopyrimidine-based inhibitors of the src family |
| 07/25/2002 | CA2406342A1 Human apoptosis-associated genes and human apoptosis-associated proteins produced thereby |
| 07/24/2002 | EP1225183A2 Human G-protein coupled receptor |
| 07/24/2002 | EP1225180A2 Process for the production of virus-inactivated human gammaglobulin G |
| 07/24/2002 | EP1224944A1 Skin immune function controlling agents |
| 07/24/2002 | EP1224938A1 Gugulipid for treating cognitive disorders, hyperglycaemia and skin disorders |
| 07/24/2002 | EP1224931A1 Use of alkanoyloxymethyl esters for inhibiting histone deacetylase |
| 07/24/2002 | EP1224861A1 Animal with the mass expression of human gene and test method by using the animal |
| 07/24/2002 | EP1224322A2 Gene sequence variations with utility in determining the treatment of disease |
| 07/24/2002 | EP1224291A1 Multiple sclerosis-related superantigen |
| 07/24/2002 | EP1224288A2 Processed human chemokines phc-1 and phc-2 |
| 07/24/2002 | EP1224285A2 27 human secreted proteins |
| 07/24/2002 | EP1224283A2 Human and rat fgf-20 genes and gene expression products |
| 07/24/2002 | EP1224281A1 37 human secreted proteins |
| 07/24/2002 | EP1224274A1 Tumor necrosis factor related receptor, tr6 |
| 07/24/2002 | EP1224262A2 Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells |
| 07/24/2002 | EP1224261A1 C-myc antisense-treated hematopoietic stem cell composition and method |
| 07/24/2002 | EP1224223A1 Immunointeractive molecules and their uses in treating subjects suffering from hev b 5 allergies |
| 07/24/2002 | EP1224222A2 Chemokine receptor |
| 07/24/2002 | EP1224220A2 Epo primary response gene 1, eprg1 |
| 07/24/2002 | EP1224215A1 NON-ANAPHYLACTIC FORMS OF GRASS POLLEN Ph1 p 6 ALLERGEN AND THEIR USE |
| 07/24/2002 | EP1224209A1 10 human secreted proteins |
| 07/24/2002 | EP1224201A1 32 human secreted proteins |
| 07/24/2002 | EP1224185A1 Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use |
| 07/24/2002 | EP1224180A2 Substituted azoles |
| 07/24/2002 | EP1224173A1 Pyrazole derivatives as cannabinoid receptor antagonists |
| 07/24/2002 | EP1224164A1 Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23 |
| 07/24/2002 | EP1223988A1 Antisense modulation of tumor necrosis factor alpha converting enzyme (tace) expression |
| 07/24/2002 | EP1223984A2 Compounds that associate on the intermolecular level and aggregate bodies that contain them |
| 07/24/2002 | EP1223979A1 Adjuvants for nucleic acid vaccines |
| 07/24/2002 | EP1223978A2 Archaeosomes as adjuvants and carriers for acellular vaccines to induce cytotoxic t lymphocyte (ctl) responses |
| 07/24/2002 | EP1223977A2 Modified plant viruses and methods of use thereof |
| 07/24/2002 | EP1223975A2 MUCOSAL DTPa VACCINES |
| 07/24/2002 | EP1223974A2 Medicament in order to induce tolerance |
| 07/24/2002 | EP1223973A2 Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization |
| 07/24/2002 | EP1223971A2 Compositions and methods for preventing and treating transplant rejection |
| 07/24/2002 | EP1223966A2 Use of gdnf for treating corneal defects |
| 07/24/2002 | EP1223965A2 Modulation of angiogenesis |
| 07/24/2002 | EP1223963A2 T-cells and molecules involved in immune regulation |
| 07/24/2002 | EP1223961A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 07/24/2002 | EP1223958A2 Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions |
| 07/24/2002 | EP1223956A1 Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| 07/24/2002 | EP1223950A2 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 07/24/2002 | EP1223933A2 5-membered heterocycle derivatives, production thereof and use thereof as medicaments |
| 07/24/2002 | EP1223929A1 Cannabimimetic indole derivatives |
| 07/24/2002 | EP1223921A2 Tissue factor antagonists and methods of use thereof |
| 07/24/2002 | EP1223915A1 Dry powder compositions having improved dispersivity |
| 07/24/2002 | EP1102743B1 Amide derivatives which are useful as cytokine inhibitors |
| 07/24/2002 | EP0835263B9 Somatostatin peptides |
| 07/24/2002 | EP0826001B1 Acellular pertussis vaccines and methods of preparation thereof |
| 07/24/2002 | EP0800579B1 Combination gene delivery vehicles |
| 07/24/2002 | EP0799044B1 Topical ophthalmic formulations containing olopatadine for treating allergic eye diseases |
| 07/24/2002 | EP0719340B1 Cloned glutamic acid decarboxylase |
| 07/24/2002 | CN1360633A Fucosyl transferase gene |
| 07/24/2002 | CN1360628A Method for transfer of antigens to dendritic cells |
| 07/24/2002 | CN1360596A Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith |
| 07/24/2002 | CN1360582A Quinazoline derivs. |
| 07/24/2002 | CN1360581A Benzoylpyridazines |
| 07/24/2002 | CN1360577A Hydroxamic acid derivs. as matrix metalloprotease inhibitors |
| 07/24/2002 | CN1360570A Phenyl sulfamate derivs. |
| 07/24/2002 | CN1360507A Conjugates and method for production thereof, and their use for transporting molecules via biological membranes |